| Trial ID: | L0953 |
| Source ID: | NCT05685394
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease
|
| Acronym: |
Dare-Esrd
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End-stage Kidney Disease
|
| Interventions: |
DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: NT-proBNP, Difference between groups in NT-proBNP change from baseline, 6 months | Secondary: Echocardiography, Difference between groups from baseline of the following: ejection fraction, e/e' ratio, global longitudinal and radial strain and indexed left ventricle mass, 6 months
|
| Sponsor/Collaborators: |
Sponsor: University of Campinas, Brazil
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-01-24
|
| Completion Date: |
2024-12-01
|
| Results First Posted: |
|
| Last Update Posted: |
2023-11-14
|
| Locations: |
Centro de Pesquisas Clínicas, Campinas, SP, 13083610, Brazil
|
| URL: |
https://clinicaltrials.gov/show/NCT05685394
|
